Asunaprevir

Generic Name
Asunaprevir
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C35H46ClN5O9S
CAS Number
630420-16-5
Unique Ingredient Identifier
S9X0KRJ00S
Background

Asunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor. It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercializati...

Indication

Asunaprevir is indicated in combination with other agents for the treatment of chronic hepatitis C in adult patients with hepatitis C virus genotypes 1 or 4 and compensated liver cirrhosis.
...

Associated Conditions
Chronic Hepatitis C Genotype 1, Genotype 4 Chronic Hepatitis C
Associated Therapies
-
Clinical Trials
Related News

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

First Posted Date
2012-04-09
Last Posted Date
2015-10-09
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
398
Registration Number
NCT01573351
Locations
🇺🇸

University Of Chicago Medical Center, Chicago, Illinois, United States

🇺🇸

Gastro One, Germantown, Tennessee, United States

🇨🇳

Local Institution, Taipei, Taiwan

and more 18 locations

Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials

First Posted Date
2011-09-02
Last Posted Date
2016-05-27
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
276
Registration Number
NCT01428063
Locations
🇺🇸

Scpmg/ Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States

🇺🇸

Mercy Medical Center, Baltimore, Maryland, United States

🇺🇸

University Of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 18 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy